In this piece, we will take a look at the five best covid treatment stocks to buy today. For more stocks, head on over to 12 Best Covid Treatment Stocks to Buy Today.
8. GSK plc (NYSE:GSK)
GSK plc (NYSE:GSK) is another British company that is headquartered in Brentford. The firm makes and sells a coronavirus vaccine called VidPrevtyn Beta.
39 of the 943 hedge funds part of Insider Monkey’s database had held a stake in the company during last year’s fourth quarter. GSK plc (NYSE:GSK)’s largest hedge fund shareholder is Peter Rathjens, Bruce Clarke, and John Campbell’s Arrowstreet Capital which owns 14 million shares that are worth $493 million.
Follow Glaxosmithkline Plc (NYSE:GSK)
Follow Glaxosmithkline Plc (NYSE:GSK)
9. Sanofi (NASDAQ:SNY)
Sanofi (NASDAQ:SNY) is a French drug manufacturer that is headquartered in Paris, France. The firm develops treatments for cancers, blood disorders, diabetes, heart problems, and other problems. It also sells a coronavirus vaccine called VidPrevtyn Beta in partnership with GSK.
Insider Monkey dug through 943 hedge fund portfolios for last year’s fourth quarter and found out that 34 had bought the company’s shares. Sanofi (NASDAQ:SNY)’s largest investor is Ken Fisher’s Fisher Asset Management which owns 13.7 million shares that are worth $667 million.
Follow Sanofi Aventis (NYSE:SNY)
Follow Sanofi Aventis (NYSE:SNY)
10. BioNTech SE (NASDAQ:BNTX)
BioNTech SE (NASDAQ:BNTX) is a German biotechnology company that is headquartered in Mainz, Germany. The firm develops treatments for cancers and rare diseases. It was also one of the first to the market with a coronavirus vaccine, which it had developed in partnership with Pfizer.
As of Q4 2022, 34 of the 943 hedge funds polled by Insider Monkey had invested in BioNTech SE (NASDAQ:BNTX). The firm’s largest investor in our database is Philippe Laffont’s Coatue Management which owns 618,231 shares that are worth $92 million.
Follow Biontech Se (NASDAQ:BNTX)
Follow Biontech Se (NASDAQ:BNTX)
11. Novavax, Inc. (NASDAQ:NVAX)
Novavax, Inc. (NASDAQ:NVAX) is an American company that is headquartered in Gaithersburg, Maryland. It makes treatments for infectious diseases such as malaria and syncytial virus. Novavax, Inc. (NASDAQ:NVAX)’s coronavirus vaccine is called Adjuvanted, and it uses spike proteins and adjuvants for treatment.
Insider Monkey studied 943 hedge fund portfolios for their December quarter of 2022 investments and found out that 20 had bought the firm’s shares. Novavax, Inc. (NASDAQ:NVAX)’s largest hedge fund shareholder is Jim Simons’ Renaissance Technologies which owns 2.8 million shares that are worth $29 million.
Follow Novavax Inc (NASDAQ:NVAX)
Follow Novavax Inc (NASDAQ:NVAX)
12. Sunshine Biopharma, Inc. (NASDAQ:SBFM)
Sunshine Biopharma, Inc. (NASDAQ:SBFM) is a pharmaceutical company headquartered in Pointe-Claire, Canada. The firm focuses on developing anticancer drugs for lung, pancreatic, and other cancers.
Sunshine Biopharma, Inc. (NASDAQ:SBFM) scored a win in February 2023 when it entered into an agreement with the Canadian McGill University’s health center hospital, the Sir Mortimer B. Davis Jewish General Hospital to develop its anticancer compound that is effective against multidrug resistant cancers; targeting a variety of different cancers such as breast cancer, lung cancer, uterine sarcoma and pancreatic cancer.
This compound, called Adva-27a, will be evaluated to determine its feasibility for a Phase 1 clinical trial, and if Sunshine Biopharma, Inc. (NASDAQ:SBFM)
determines that it is ready for a trial, then the company has found a willing partner in the form of the Jewish General Hospital to set up a new agreement for a trial.
Research for Adva-27a will be conducted by Dr. Gerald Baptist, who is the head of the Jewish General Hospital’s oncology department and the director of McGill’s Center for Translational Cancer Research in Cancer. The company’s CEO, Dr. Steve Slilaty, expressed optimism that his company will be able to work with the hospital past the research agreement and in a more collaborative capacity into the future.
Follow Sunshine Biopharma Inc (OTCMKTS:SBFM)
Follow Sunshine Biopharma Inc (OTCMKTS:SBFM)
Disclosure: None. The author received no additional compensation for this piece except for what is typically made by Insider Monkey. This is a paid sponsored article and is not intended to be investing advice. We don’t guarantee the accuracy of the statements made in this article. Insider Monkey may receive monetary compensation from Sunshine Biopharma Inc or its agency for publishing this article. Insider Monkey doesn’t recommend purchase/sale of any securities, cryptocurrencies, or ICOs. Please get in touch with a financial professional before making any financial decisions. You understand that Insider Monkey doesn’t accept any responsibility and you will be using the information presented here at your own risk. You acknowledge that this disclaimer is a simplified version of our Terms of Use, and by accessing or using our site, you agree to be bound by all of its terms and conditions. If at any time you find these terms and conditions unacceptable, you must immediately leave the Site and cease all use of the Site.
Insider Monkey focuses on uncovering the best investment ideas of hedge funds and investors. Please subscribe to our daily free newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below
